eligibility_summary
Adults (≥18) with relapsed/refractory mesothelin‑positive solid tumors, ≥1 RECIST v1.1 lesion, ECOG 0–1, life expectancy ≥3 months, adequate blood/liver/coagulation/renal/cardiac (LVEF>45%) and SpO2>92%, agree to contraception and consent. Exclude recent systemic therapy/steroids/biologics/vaccines/trials, pregnancy, active HBV/HCV/HIV/syphilis, unresolved toxicities, prior allogeneic transplant or anti‑MSLN CAR‑T, unstable CNS mets, major illness, severe drug allergy, recent surgery, other recent cancer, neuropsychiatric disease, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Anti-mesothelin (MSLN) CAR-T cells (UCLM802), an autologous cellular immunotherapy of gene‑modified T cells engineered with a chimeric antigen receptor that binds mesothelin. Mechanism: CAR engagement of mesothelin on tumor cells triggers T‑cell activation, cytokine release, and cytotoxic killing, lymphodepleting chemotherapy is used to enhance CAR-T expansion, some cohorts assess IV vs local delivery and addition of immune checkpoint inhibitors. Targets: Mesothelin-expressing solid tumor cells (e.g., mesothelioma, pancreatic, biliary, lung, ovarian, gastric, colorectal). Pathways/cells: CAR-activated T cells, host lymphocyte depletion, immune checkpoint pathways in combo cohort.